Phoenix Biopharma

Phoenix Biopharma is a clinical-stage biotechnology company focused on developing differentiated therapies for oncology and immunological diseases. The company's lead asset is imgatuzumab (also known as GA201), a humanized, glycoengineered, anti-EGFR monoclonal antibody designed with enhanced antibody-dependent cellular cytotoxicity (ADCC) and phagocytosis (ADCP) to improve efficacy in solid tumors. Phoenix Biopharma acquired imgatuzumab through its 2023 acquisition of the French biotech firm Pega-One, which had licensed the molecule from Roche. Currently, imgatuzumab is being evaluated in Phase 2 clinical trials for the treatment of cutaneous squamous cell carcinoma (CSCC) and other hard-to-treat solid tumors. Led by industry veterans with extensive experience in global pharmaceutical strategy and development, Phoenix Biopharma aims to address significant unmet needs in the oncology space through targeted acquisitions and clinical advancement.